Alternative Data for Annexon
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 3 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Employee Rating | 40 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 10 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 1,179 | Sign up | Sign up | Sign up |
| X Followers | 323 | Sign up | Sign up | Sign up |
| X Mentions | 7 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 17 | Sign up | Sign up | Sign up |
| Linkedin Employees | 118 | Sign up | Sign up | Sign up |
About Annexon
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders.
| Price | $5.72 |
| Target Price | Sign up |
| Volume | 3,419,498 |
| Market Cap | $844M |
| Year Range | $2.05 - $6.96 |
| Dividend Yield | 0% |
| Analyst Rating | 100% buy |
| Industry | Biotechnology |
In the news
 |
Annexon Offers A High-Risk, High-Reward Play On A New Approach To Complement-Mediated DiseasesJanuary 23 - SeekingAlpha |
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)January 16 - GlobeNewswire |
|
 |
Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 16 - SeekingAlpha |
|
Annexon, Inc. (ANNX) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14 - SeekingAlpha |
 |
Annexon highlights its 2026 strategic prioritiesJanuary 12 - Thefly.com |
|
Annexon submits MAA to EMA for tanruprubartJanuary 8 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -55M | -54M | -0.370 |
| Q2 '25 | 0 | 910,000 | -910,000 | -49M | -51M | -0.340 |
| Q1 '25 | 0 | 900,000 | -900,000 | -54M | -57M | -0.370 |
| Q4 '24 | 3.4M | 0 | 1.7M | -49M | -52M | -0.330 |
| Q3 '24 | 0 | 870,000 | -870,000 | -35M | -39M | -0.250 |
Insider Transactions View All
| Carson William H. filed to buy 62,405 shares at $5.7. March 12 '26 |
| Lew Jennifer filed to sell 170,700 shares at $5.4. March 4 '26 |
| Dananberg Jamie filed to sell 123,582 shares at $5.4. March 4 '26 |
| Overdorf Michael filed to sell 182,625 shares at $5.4. March 4 '26 |
| Yednock Ted filed to sell 154,161 shares at $5.4. March 4 '26 |
Similar companies
Read more about Annexon (ANNX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Annexon
The Market Cap of Annexon is $844M.
Currently, the price of one share of Annexon stock is $5.72.
The ANNX stock price chart above provides a comprehensive visual representation of Annexon's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Annexon shares. Our platform offers an up-to-date ANNX stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Annexon (ANNX) does not offer dividends to its shareholders. Investors interested in Annexon should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Annexon are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
